Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders with dysregulated myeloid blood cell production and propensity for transformation to acute myeloid leukemia, thrombosis, and bleeding. Acquired mutations in JAK2, MPL, and CALR converge on hyperactivation of Janus kinase 2 (JA...
Main Authors: | Sime Brkic, Sara C. Meyer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2021-01-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000516 |
Similar Items
-
Novel therapeutics in myeloproliferative neoplasms
by: Sangeetha Venugopal, et al.
Published: (2020-12-01) -
Targeted therapies for myeloproliferative neoplasms
by: Bing Li, et al.
Published: (2019-07-01) -
Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
by: Tariq I. Mughal, et al.
Published: (2018-10-01) -
Aetiology of Myeloproliferative Neoplasms
by: Mary Frances McMullin, et al.
Published: (2020-07-01) -
Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
by: Alessandra Iurlo, et al.
Published: (2019-04-01)